Hydralazine

From Wikipedia, the free encyclopedia

Hydralazine
Systematic (IUPAC) name
1-hydrazinophthalazine
Identifiers
CAS number 86-54-4
ATC code C02DB02
PubChem 3637
Chemical data
Formula C8H8N4 
Mol. mass 160.176 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism Hepatic
Half life 2-4 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral, intravenous

Hydralazine hydrochloride (1-hydrazinophthalazine monohydrochloride; Apresoline) is a direct-acting smooth muscle relaxant used to treat hypertension by acting as a vasodilator primarily in arteries and arterioles. By relaxing vascular smooth muscle, vasodilators act to decrease peripheral resistance, thereby lowering blood pressure.[1]

Contents

[edit] Mechanism

The mechanism of action of hydralazine is not well known. It interferes with the action the second messenger inositol triphosphate, limiting calcium release from the sarcoplasmic reticulum of smooth muscle. This results in an arterial and arteriolar relaxation.[2]

An exam revision source declares that hydralazine works through a cGMP-mediated mechanism, resulting in smooth muscle relaxation.[3]

[edit] Clinical Use

Hydralazine is not used as a primary drug for treating hypertension because it elicits a reflex sympathetic stimulation of the heart (the baroreceptor reflex). The sympathetic stimulation may increase heart rate and cardiac output, and may cause angina pectoris or myocardial infarction.[1] Hydralazine may also increase plasma renin concentration, resulting in fluid retention. In order to prevent these undesirable side effects, hydralazine is generally prescribed in combination with a beta-blocker (e.g., propranolol) and a diuretic.[1]

Hydralazine is used to treat severe hypertension, but again, it is not a first line therapy for essential hypertension. However, hydralazine is the first line therapy for hypertension in pregnancy, with methyldopa.[3]

[edit] Side effects

Common side effects include:

Patients given hydralazine over a peroid of six months may develop a lupus-like syndrome or other immune related diseases that generally are reversible with withdrawal.[1] Hydralazine is differentially acetylated by fast and slow acetylator phenotypes thus incidence of lupus-like disease in slow acetylators.

[edit] References

  1. ^ a b c d Harvey, Richard A., Pamela A. Harvey, and Mark J. Mycek. Lippincott's Illustrated Reviews: Pharmacology. 2nd ed. Philadelphia: Lipincott, Williams & Wilkins, 2000. 190.
  2. ^ Rang, Dale, Ritter and Flower. Pharmacology. 6th Ed, 2007.
  3. ^ a b Bhushan, Vikas, Tao T. Lee, and Ali Ozturk. First Aid for the USMLE Step 1. New York: McGraw-Hill Medical, 2007. 251.